This website provides educational information about medicines and active ingredients. It does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Blog

DONEPEZIL (Aricept): What is used for?

[toc] What is Donepezil? Donepezil is an active ingredient used in the treatment of Alzheimer’s disease. The product ingredient is Donepezil hydrochloride (hcl). The brand names of Donepezil in United States are: Aricept, Aricept ODT....

Educational content Use this article as a starting point for understanding the topic.
Check with a professional Ask a doctor or pharmacist before changing any medicine.
Safety first Side effects, interactions and risks depend on each person.
Medical disclaimer

This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.

[toc]

What is Donepezil?

Donepezil is an active ingredient used in the treatment of Alzheimer’s disease. The product ingredient is Donepezil hydrochloride (hcl).

The brand names of Donepezil in United States are: Aricept, Aricept ODT.

Donepezil Mechanism of Action (MOA)

Specific and reversible inhibitor of acetylcholinesterase, predominant cholinesterase in the brain.

Therapeutic indications, uses and benefits of Donepezil

Symptomatic treatment of mild to moderately severe Alzheimer’s disease.

Donepezil Dosage

Oral.
One shot before going to bed.
Adults and the elderly: 5 mg/day for 1 month, evaluate evolution and increase to 10 mg/day.
Children not recommended.

Contraindications

  • Hypersensitivity.
  • Piperidine derivatives.
  • Pregnancy.

Donepezil warnings and precautions

  • Anesthesia.
  • Accentuates muscle relaxation succinylcholine type.
  • Supraventricular cardiac conduction alterations.
  • History of asthma.
  • Obstructive pulmonary disease, ulcerative disease or concomitant with NSAIDs.
  • Exacerbate or induce extrapyramidal symptoms.
  • Risk of convulsions and lower urinary tract obstruction.
  • Risk of neuroleptic malignant syndrome, if symptoms indicative of neuroleptic malignant syndrome develop, discontinue treatment.
  • Danger of rhabdomyolysis, more frequent at the beginning of treatment or when increasing the dose.

Interactions with Donepezil

  • Metabolism inhibited by: CYP3A4 and 2D6 inhibitors.
  • Reduced levels by: rifampicin, phenytoin, carbamazepine and alcohol.
  • Synergistic activity with: succinylcholine, other neuromuscular blockers, cholinergic agonists and ß-blockers.

Pregnancy and Donepezil

Contraindicated.

Breastfeeding

Avoid.
This active ingredient is excreted in milk in rats. It is not known whether Donepezil is excreted in human breast milk and no studies have been done in breastfeeding women. Therefore, women taking this medication should not provide breast-feeding.

Effects on driving ability

Alzheimer’s disease can cause a gradual deterioration in driving ability or compromise the ability to use machines. In addition, this active ingredient may cause dizziness and drowsiness, mainly when treatment is started or when the dose is increased.

Donepezil’s influence on the ability to drive and use machines is mild or moderate. Therefore, the physician will regularly evaluate the ability of patients with dementia to continue to drive or operate complex machinery.

Adverse reactions and side effects of Donepezil

Diarrhea, muscle cramps, fatigue, pain.
Nausea, vomiting, insomnia, syncope, dizziness.
Abdominal discomfort, urinary incontinence, rash, itching.
Headache, anorexia, common cold.
Hallucinations, agitation, aggressive behavior, abnormal dreams and nightmares, accidents.

Overdose

Tertiary anticholinergic antidote such as atropine.
An intravenous (IV) injection of atropine sulfate is recommended as follows: initial dose of 1-2 mg, with subsequent doses based on clinical response.

⭐⭐⭐⭐⭐ VIDEO OF DONEPEZIL/ARICEPT (DRUG)

Source: The content of this active ingredient has been written taking into account the clinical and molecular information of all medicines authorised and marketed in the United States under the Unique Ingredient Identifier (UNII) by the Substance Registration System (SRS) of the Food and Drug Administration (FDA) and the United States Pharmacopeia (USP).

In order to know in detail the information authorized by the FDA for each drug, you should consult the corresponding medication guide authorized by the FDA.

Resources:

UNII: 8SSC91326P
ChemIDplus
DrugPortal
PubChem CID: 3152
NCI Thesaurus: C66874

 

 

Editorial note Active Ingredients Online Editorial Team This article is prepared as educational medicine information for general readers. It is written to support understanding of active ingredients, medicine uses, possible side effects, precautions and safety-related questions.
Published: August 23, 2019 Updated: August 26, 2019 Educational content

Medical disclaimer

This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.

Sources and verification

Medicine information can change by country, product formulation and official safety updates. For personal decisions, verify details with official medicine information and a qualified healthcare professional. These official resources can help readers check medicine safety information:

To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.

Final note

Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.

See also...
Ask a Doctor Online medical questions